Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

NCT06487039 is registered in ClinicalTrials.gov with EyebioKorea, Inc. as lead sponsor.

NCT NCT06487039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06487039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomization, Double-blind, Parallel, Multicenter-Phase 2a Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
Lead sponsor
EyebioKorea, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 1, 2024
Completion date
January 31, 2026
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)